Patents by Inventor Elsa A.J.M. Goulmy

Elsa A.J.M. Goulmy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080206268
    Abstract: Peptide sequences constituting T-cell epitopes of minor Histocompatibility antigen, HA-1. HA-1 is associated with Graft versus Host Disease. The peptides and their derivatives find many uses, for instance, in bone marrow transplantation, organ transplantation and in treatment of leukemia and non-hematopoietic tumors. The peptide and/or its derivatives can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. HA-1 is expressed by non-hematopoietic tumor cells. While absent in normal epithelial cells, tumor cells and tumor cell lines, particularly from epithelial origin, express HA-1 and are recognized by HA-1 cytotoxic T-cells. The invention provides means and methods for HA-1 specific immunotherapy for HA-1-positive patients with non-hematopoietic tumor cells.
    Type: Application
    Filed: February 20, 2007
    Publication date: August 28, 2008
    Inventors: Elsa A.J.M. Goulmy, Donald F. Hunt, Victor H. Engelhard
  • Publication number: 20040092446
    Abstract: Peptide sequences constituting T-cell epitopes of minor Histocompatibility antigen, HA-1. HA-1 is associated with Graft versus Host Disease. The peptides and their derivatives find many uses, for instance in bone marrow transplantation, organ transplantation and in treatment of leukemia and non-hematopoietic tumors. The peptide and/or its derivatives can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. HA-1 is expressed by non-hematopoietic tumor cells. While absent in normal epithelial cells, tumor cells and tumor cell lines, particularly from epithelial origin, express HA-1 and are recognized by HA-1 cytotoxic T cells. The invention provides means and methods for HA-1 specific immunotherapy for HA-1 positive patients with non-hematopoietic tumor cells.
    Type: Application
    Filed: July 18, 2003
    Publication date: May 13, 2004
    Inventors: Elsa A.J.M. Goulmy, Donald F. Hunt, Victor H. Engelhard